Articles related to Oncology, Surgical

Research projects a 30% increase in early-onset cancers by 2030, highlighting the urgent need for adjusted screening protocols and preventive strategies in younger populations.

Recent clinical trials demonstrate significant advances in targeted therapies for NETs, with 177Lu-Dotatate showing particular promise as a first-line treatment option for higher-grade GEP-NETs.

One in eight women will develop breast cancer in her lifetime, with risk-reducing medications showing up to 65% reduction in annual incidence, yet these interventions remain vastly underutilized in clinical practice.

Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.

The discovery of I-NCMs’ ability to simultaneously patrol blood vessels and infiltrate tumor environments opens new possibilities for treating therapy-resistant cancers.

Workplace exposure to harmful chemicals remains a significant risk factor for bladder cancer, particularly affecting specific occupations and requiring targeted prevention strategies.